JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on November 30, 2007; DOI: 10.1124/jpet.107.132241


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.107.132241v1
324/3/1102    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Murray, I. A
Right arrow Articles by Perdew, G. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murray, I. A
Right arrow Articles by Perdew, G. H.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*OMEPRAZOLE


Received for publication September 28, 2007.
Revised November 10, 2007.
Accepted for publication November 29, 2007.

Omeprazole stimulates the induction of human insulin-like growth factor binding protein-1 through Ah receptor activation

Iain A Murray 1 Gary H. Perdew 2*

1 The Pennsylvania State University 2 Pennsylvania State University

* Address correspondence to: E-mail: ghp2{at}psu.edu

Abstract

Omeprazole (5-methoxy-2-{(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylsulfinyl}-3H-benzoimidazole), a benzoimidazole-derived gastric H+/K+-ATPase proton pump inhibitor (PPI) extensively prescribed for the treatment of gastro-esophageal acid reflux disease; can stimulate the expression of CYP1A1 via activation of the human aryl hydrocarbon receptor (hAhR) in an apparent non-ligand binding fashion. Here, we have examined the effect of non-classical i.e. non-ligand binding, AhR activation by omeprazole upon human insulin-like growth factor binding protein-1 (hIGFBP-1), a secreted phosphoprotein involved in regulation of IGF-I & II bioavailability and mitogenic activity. Analysis of the proximal promoter of the hIGFBP-1 gene reveals the presence of an AhR binding/dioxin response element (DRE). Quantitative mRNA analysis revealed hIGFBP-1 expression to be responsive to both ligand (TCDD) and non-ligand (omeprazole) modes of hAhR activation in the human hepatocarcinoma HepG2 cell line. Furthermore, mutagenesis of the DRE renders the hIGFBP-1 promoter unresponsive to both compounds in HepG2 cells. Similarly, siRNA-mediated hAhR ablation inhibits TCDD and omeprazole-dependent hIGFBP-1 induction, as determined by quantitative mRNA analysis. Co-treatment with cycloheximide further suggests a direct transcriptional role for hAhR at the hIGFBP-1 promoter. Omeprazole exposure prompted a significant increase in both hIGFBP-1 mRNA and secreted protein from HepG2 cells. Additionally, we present in vitro evidence indicating that omeprazole at a concentration comparable to that found circulating in subjects undergoing PPI therapy can stimulate the expression of hIGFBP-1. These data demonstrate that activation of hAhR by pharmaceuticals such as omeprazole can alter IGFBP-1 expression and thus may influence IGFBP-1 dependent physiological processes.


Key words: Ah receptor, Dioxin response element, HepG2, IGFBP-1, Transcription, omeprazole





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.